Michael Doumet

Michael focuses his practice on mergers and acquisitions and private equity transactions, with particular emphasis on leveraged buyouts, private acquisitions, hostile takeovers and divestitures, both domestic and cross-border.

Michael regularly represents corporate and private equity clients in the healthcare/pharmaceuticals, TMT, energy and chemicals industries.

• Advised CVC Capital Partners on the EUR 3.6 billion reorganization of Elsan Group alongside KKR, Téthys and management (Healthcare)*
• Advised CVC Capital Partners on the EUR 2.2 billion sale of the Parex Group to Sika AG (Construction chemicals)*
• Advised CVC Capital Partners on the EUR 1.2 billion acquisition of Linxens from Astorg (Smartcard connectors)*
• Advised Téthys, CPPIB and Montagu on the EUR 2.2 billion reorganization of the Galileo Group (Education)*
• Advised InfraVia on the setup and acquisition of a radiotherapy business (Healthcare)*
• Advised Montefiore and LFPI on the sale of Interflora to PAI Partners (Flowers)*
• Advised Orange on the EUR 2.6 billion set up and sale of 50% of Orange Concessions to CDC, CNP Assurances and EDF (Fiber optic)*
• Advised Orange on the contemplated disposal of a business division (Entertainment)*
• Advised Orange on the contemplated bid for the acquisition of 45% of TDF (TowerCo)*
• Advised Vinci on the EUR 5 billion acquisition of the energy business of ACS (Energy and construction)*

* Matters handled prior to joining Baker McKenzie

View All